Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Working with families: Lessons from a Canadian registry of palivizumab use

Ian Mitchell, Parco Chan, Abby Li, Hao Yi, Bosco Paes, Krista Lanctot
European Respiratory Journal 2015 46: PA3626; DOI: 10.1183/13993003.congress-2015.PA3626
Ian Mitchell
1Paediatrics, University of Calgary, Calgary, AB Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parco Chan
2MORE Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abby Li
2MORE Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Yi
2MORE Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bosco Paes
3Paediatrics, McMaster University, Hamilton, ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krista Lanctot
2MORE Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Palivizumab is a monoclonal antibody for prevention of respiratory syncytial virus (RSV) infections, requiring therapeutic levels and a strict dosing schedule.

Objectives: To investigate adherence and its impact on outcomes.

Methods: Infants were enrolled into the Canadian RSV Evaluation Study of Palivizumab (CARESS) between 2005 and 2014. Monthly telephone interviews throughout the RSV season collected data on injection dates, respiratory illness related hospitalizations, and RSV testing. Statistical analyses identified differences between groups.

Results: 19198 infants received a total of 83244 injections in the 2005-2013 seasons. Adherence, receiving >=5 injections or 100% of expected injections within the appropriate intervals., occurred in 11691 infants (60.9%).Adherence was more likely (Exp(B) [95%CI], p-value) with higher maternal education (1.74 [1.50-2.03], <0.0005) and having siblings (1.07 [1.01-1.14], 0.03).Adherence was less likely in Aboriginals (0.48 [0.41-0.56], maternal smoking (0.78[0.71-0.86], <0.0005), and older infants (0.97 [0.94-0.99], 0.02)when adjusted for the significant demographic factors. Despite a non-significant association between compliance and RSVH (0.89 [0.68-1.16], 0.38), there was a significant difference (p<0.0005) in total duration of hospitalization between groups, with infants with acceptable adherence staying on average 7.79 ± 8.48 days and infants staying 16.64 ± 30.04 days.

Conclusions: Adherence to a palivizumab regimen is important. Poorer adherence affects health outcomes such as longer hospitalizations. Targeted interventions for families who have problems with adherence are needed to improve adherence to the palivizumab regimen.

  • Bronchiolitis
  • Vaccination
  • Epidemiology
  • Copyright ©ERS 2015
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Working with families: Lessons from a Canadian registry of palivizumab use
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Working with families: Lessons from a Canadian registry of palivizumab use
Ian Mitchell, Parco Chan, Abby Li, Hao Yi, Bosco Paes, Krista Lanctot
European Respiratory Journal Sep 2015, 46 (suppl 59) PA3626; DOI: 10.1183/13993003.congress-2015.PA3626

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Working with families: Lessons from a Canadian registry of palivizumab use
Ian Mitchell, Parco Chan, Abby Li, Hao Yi, Bosco Paes, Krista Lanctot
European Respiratory Journal Sep 2015, 46 (suppl 59) PA3626; DOI: 10.1183/13993003.congress-2015.PA3626
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Cytokine and chemokine profile in a cohort of children with community acquired pneumonia
  • Change in the management of pneumonia with pleural effusion in children following implementation of a new decision tree
  • Technology depended children. Quality of life, days of hospitalization and cost effect from a home care program
Show more 7.4 Paediatric Respiratory Infection and Immunology

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society